149 related articles for article (PubMed ID: 37521829)
21. AL amyloidosis: The effect of fluorescent in situ hybridization abnormalities on organ involvement and survival.
Ozga M; Zhao Q; Benson D; Elder P; Williams N; Bumma N; Rosko A; Chaudhry M; Khan A; Devarakonda S; Kahwash R; Vallakati A; Campbell C; Parikh SV; Almaani S; Prosek J; Bittengle J; Pfund K; LoRusso S; Freimer M; Redder E; Efebera Y; Sharma N
Cancer Med; 2021 Feb; 10(3):965-973. PubMed ID: 33347707
[TBL] [Abstract][Full Text] [Related]
22. Multiplex ligation-dependent probe amplification and fluorescence in situ hybridization are complementary techniques to detect cytogenetic abnormalities in multiple myeloma.
Alpar D; de Jong D; Holczer-Nagy Z; Kajtar B; Savola S; Jakso P; David M; Kosztolanyi S; Kereskai L; Pajor L; Szuhai K
Genes Chromosomes Cancer; 2013 Sep; 52(9):785-93. PubMed ID: 23720363
[TBL] [Abstract][Full Text] [Related]
23. The Utilization of Karyotyping, iFISH, and MLPA for the Detection of Recurrence Genetic Aberrations in Multiple Myeloma.
Sommaluan S; Rerkamnuaychoke B; Pauwilai T; Chancharunee S; Onsod P; Pornsarayuth P; Chareonsirisuthigul T; Tammachote R; Siriboonpiputtana T
Asian Pac J Cancer Prev; 2017 Nov; 18(11):3135-3142. PubMed ID: 29172291
[TBL] [Abstract][Full Text] [Related]
24. Cytogenetic testing by fluorescence in situ hybridization is improved by plasma cell sorting in multiple myeloma.
Ha J; Cho H; Lee TG; Shin S; Chung H; Jang JE; Kim SJ; Cheong JW; Lee ST; Kim JS; Choi JR
Sci Rep; 2022 May; 12(1):8287. PubMed ID: 35585097
[TBL] [Abstract][Full Text] [Related]
25. [Comparative study of genetic aberrations in human multiple myeloma cell lines and newly diagnosed MM by fluorescence in situ hybridization].
An G; Xie ZQ; Li CH; Li Q; Yi SH; Qiu LG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1505-10. PubMed ID: 21176360
[TBL] [Abstract][Full Text] [Related]
26. [Application of CD138 Immunomagnetic Sorting Myeloma Cells Combined with Fluorescence in Situ Hybridization for Detecting Cytogenetic Abnormalities of Multiple Myeloma].
Gao L; Liu Q; Shi Y; Dang H; He Q; Wang Z; Feng L; Li Y; Wang XY; Li N; Song WJ; Wang YL; Kong S; Lu J; Huang XJ; Lai YY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):807-812. PubMed ID: 28641640
[TBL] [Abstract][Full Text] [Related]
27. Targeting plasma cells improves detection of cytogenetic aberrations in multiple myeloma: phenotype/genotype fluorescence in situ hybridization.
Slovak ML; Bedell V; Pagel K; Chang KL; Smith D; Somlo G
Cancer Genet Cytogenet; 2005 Apr; 158(2):99-109. PubMed ID: 15796956
[TBL] [Abstract][Full Text] [Related]
28. Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study.
Oh S; Koo DH; Kwon MJ; Kim K; Suh C; Min CK; Yoon SS; Shin HJ; Jo DY; Kwak JY; Kim JS; Sohn SK; Joo YD; Eom HS; Kim SH; Kim YS; Kim C; Mun YC; Kim H; Lee DS; Lee JH;
Ann Hematol; 2014 Aug; 93(8):1353-61. PubMed ID: 24671365
[TBL] [Abstract][Full Text] [Related]
29. [Cytogenetic abnormalities and prognosis of 532 patients with multiple myeloma].
Wu H; Zhang H; He HY; Jiang H; Zhao YY; An R; He J; Li R; Lu J; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2017 Sep; 38(9):739-743. PubMed ID: 29081188
[No Abstract] [Full Text] [Related]
30. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.
Avet-Loiseau H; Attal M; Moreau P; Charbonnel C; Garban F; Hulin C; Leyvraz S; Michallet M; Yakoub-Agha I; Garderet L; Marit G; Michaux L; Voillat L; Renaud M; Grosbois B; Guillerm G; Benboubker L; Monconduit M; Thieblemont C; Casassus P; Caillot D; Stoppa AM; Sotto JJ; Wetterwald M; Dumontet C; Fuzibet JG; Azais I; Dorvaux V; Zandecki M; Bataille R; Minvielle S; Harousseau JL; Facon T; Mathiot C
Blood; 2007 Apr; 109(8):3489-95. PubMed ID: 17209057
[TBL] [Abstract][Full Text] [Related]
31. Cytogenetic and molecular aberrations of multiple myeloma patients: a single-center study in Singapore.
Lim AS; Lim TH; See KH; Ng YJ; Tan YM; Choo NS; Lim SX; Yee Y; Lau LC; Tien SL; Sathish K; Tan DC
Chin Med J (Engl); 2013; 126(10):1872-7. PubMed ID: 23673102
[TBL] [Abstract][Full Text] [Related]
32. Target fluorescence in-situ hybridization (Target FISH) for plasma cell enrichment in myeloma.
Ma ES; Wang CL; Wong AT; Choy G; Chan TL
Mol Cytogenet; 2016; 9():63. PubMed ID: 27532015
[TBL] [Abstract][Full Text] [Related]
33. Role of cytogenetic abnormalities detected by fluorescence
Shetty D; Jain H; Rohil Y; Khattry N; Sengar M; Bagal B; Jain H; Gokarn A; Punatar S; Avinash Bonda VN; Subramanian PG
Indian J Med Res; 2021 Apr; 153(4):475-483. PubMed ID: 34380794
[TBL] [Abstract][Full Text] [Related]
34. Interphase fluorescence in situ hybridization (FISH) as a powerful tool for the detection of aneuploidy in multiple myeloma.
Flactif M; Zandecki M; Laï JL; Bernardi F; Obein V; Bauters F; Facon T
Leukemia; 1995 Dec; 9(12):2109-14. PubMed ID: 8609724
[TBL] [Abstract][Full Text] [Related]
35. Hyperdiploid Multiple Myeloma with Novel Complex Structural Chromosome Abnormalities Associated with Poor Prognosis : A Rare Case Report.
Ankathil R; Foong E; Siti-Mariam I; Norhidayah R; Nazihah MY; Sangeetha V; Hariharan S; Azlan H
Int J Hematol Oncol Stem Cell Res; 2021 Jul; 15(3):199-205. PubMed ID: 35083001
[TBL] [Abstract][Full Text] [Related]
36. Risk stratification of plasma cell neoplasm: insights from plasma cell-specific cytoplasmic immunoglobulin fluorescence in situ hybridization (cIg FISH) vs. conventional FISH.
Dong H; Yang HS; Jagannath S; Stephenson CF; Brenholz P; Mazumder A; Chari A
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):366-74. PubMed ID: 22658896
[TBL] [Abstract][Full Text] [Related]
37. [Molecular cytogenetic analyses of patients with plasma cell myeloma in Tolna and Baranya counties in Hungary].
Kosztolányi S; Horváth B; Hosnyánszki D; Kereskai L; Sziládi E; Jáksó P; Alizadeh H; Szuhai K; Alpár D; Kajtár B
Orv Hetil; 2019 Jun; 160(24):944-951. PubMed ID: 31433233
[TBL] [Abstract][Full Text] [Related]
38. Antigen Expression Patterns of Plasma Cell Myeloma: An Association of Cytogenetic Abnormality and International Staging System (ISS) for Myeloma.
Shin SY; Lee ST; Kim HJ; Kim SJ; Kim K; Kang ES; Kim SH
J Clin Lab Anal; 2015 Nov; 29(6):505-10. PubMed ID: 25277787
[TBL] [Abstract][Full Text] [Related]
39. Identification of Prognostically Relevant Chromosomal Abnormalities in Routine Diagnostics of Multiple Myeloma Using Genomic Profiling.
Kjeldsen E
Cancer Genomics Proteomics; 2016; 13(2):91-127. PubMed ID: 26912802
[TBL] [Abstract][Full Text] [Related]
40. Recurrent Cytogenetic Abnormalities in Multiple Myeloma.
Chan NC; Chan NP
Methods Mol Biol; 2017; 1541():295-302. PubMed ID: 27910031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
